Phase I DNA Immunotherapy Trial Initiated in Adults with Breast, Lung, and Pancreatic Cancer
the Cancer Therapy Advisor take:
High levels of hTERT (human telomerase reverse transcriptase) expression are found in 85% of human cancers, and is therefore a significant target for cancer treatment.
Therefore, Inovio Pharmaceuticals recently announced it has initiated a phase I trial of hTERT DNA immunotherapy alone or in combination with an interleukin-12 immune activator (INO-9012; also from Inovio), which will be conducted at the University of Pennsylvania's Abramson Cancer Center.
In a previous study that looked at the activity of the drug in monkeys, who have similar TERT to humans, strong immune responses were observed and showed the potential to destroy cancer cells. The phase I trial is an open-label, dose-escalation study in patients with breast, lung, or pancreatic cancer who are at risk for relapse after surgery or chemotherapy/radiation.
The safety and tolerability of INO-1400 alone or in combination with INO-9012 will be evaluated, with a secondary objective to determine immune responses and evaluate immunotherapy-induced changes. Lung, breast, and pancreatic cancers were selected for this study because they have the first, third, and fourth highest mortality rates, and patients with these diseases often relapse despite surgery and adjuvant therapy.
The hope is that this drug will be yet another weapon in the armament of immunotherapies aimed at empowering the patient’s own immune system to fight their cancer.
High levels of hTERT expression are found in 85% of human cancers.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed